Sun Pharmaceutical Industries Ltd reported a 27% year-on-year increase in consolidated net profit for the quarter ending June 30, 2026. Net profit reached ₹2,894.79 crore during this period. Revenue from operations grew by 10.5% to ₹15,299.88 crore. The India formulations business drove growth with a 16% rise in sales.
Sun Pharma missed market expectations despite the profit growth. U.S. formulations sales declined by 10% to $427 million. Pricing pressures in the generics business caused the revenue dip in the American market.
Company shares fell by nearly 1.5% following the announcement. The stock price movement indicated a cautious investor reaction to the earnings report.